1 天
MedPage Today on MSNLong-Acting ART Could Prevent More Infant HIV Infections in ZimbabweProviding long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence challenges may be ...
Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...
When it came to innovations in biotech, there was a clear winner: lenacapavir, a drug that was found to prevent HIV infections in 100% of the women and girls who received it in a clinical trial.
El Mundo on MSN4 天
New advance against HIV: a single annual injection against the infectionData from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
A new method is developed to track dormant HIV-infected cells. This breakthrough may lead to new treatments that eliminate ...
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.
3 天
LGBTQ Nation on MSNOnce-a-year shot for HIV protection passes early safety trialAn annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果